Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Drug, Biological
Study Type: Observational
SUMMARY

The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries). The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).

Eligibility
Participation Requirements
Sex: Female
Healthy Volunteers: f
View:

• Participant must have a diagnosis of MS

• Documentation that the participant was one of the following:

‣ exposed to DRF at any time from 2 weeks after the first day of their LMP (i.e., conception date) up through any time during pregnancy. (If exact exposure dates are unknown, the reporter must be able to specify or estimate trimester of exposure).

⁃ unexposed to any DMT during pregnancy, defined as having never received DMT therapy; discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP (i.e., conception date); or discontinued a non Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP (i.e., conception date)

• Participants with knowledge of the outcome of the pregnancy (e.g., pregnancy loss or live birth)

Locations
United States
Colorado
University of Colorado Anschutz Medical Campus
RECRUITING
Aurora
North Carolina
IQVIA US Office
RECRUITING
Durham
Other Locations
Australia
Austin Hospital
RECRUITING
Heidelberg
Germany
Katholisches Klinikum Bochum
RECRUITING
Bochum
Ireland
St Vincent's University Hospital
RECRUITING
Dublin
Spain
Hospital Universitario Ramon y Cajal
RECRUITING
Madrid
Switzerland
Inselspital
RECRUITING
Bern
Contact Information
Primary
US Biogen Clinical Trial Center
clinicaltrials@biogen.com
866-633-4636
Backup
Global Biogen Clinical Trial Center
clinicaltrials@biogen.com
Time Frame
Start Date: 2023-10-27
Estimated Completion Date: 2032-07-06
Participants
Target number of participants: 908
Treatments
Diroximel Fumarate
Pregnant women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
Disease Modifying Therapy (DMTs) Exposed
Pregnant women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries) at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
DMTs Unexposed
Pregnant women who were unexposed to DMT which is defined as either never received a DMT or discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP or discontinued a non-Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP.
Dimethyl Fumarate
Pregnant women with MS who were exposed to DMF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
Women Without MS
Pregnant women with external, general population comparators.
Related Therapeutic Areas
Sponsors
Leads: Biogen

This content was sourced from clinicaltrials.gov